{"id":435351,"date":"2021-02-12T17:08:10","date_gmt":"2021-02-12T22:08:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=435351"},"modified":"2021-02-12T17:08:10","modified_gmt":"2021-02-12T22:08:10","slug":"appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/","title":{"rendered":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021<\/b><\/p>\n<p>HALIFAX, Nova Scotia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAppili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the third quarter of its fiscal year 2021, which ended December 31, 2020.\n<\/p>\n<p>\nThird quarter and recent operational highlights include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Joins-Dr.-Reddy%25E2%2580%2599s%252C-Global-Response-Aid%252C-and-FUJIFILM-in-Advancing-Avigan%25C2%25AE-Tablets-for-the-Potential-Treatment-of-COVID-19&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=Signing+a+collaboration%2C+development%2C+and+supply+agreement&amp;index=1&amp;md5=62ca200bed17979c201e582bce699666\">Signing a collaboration, development, and supply agreement<\/a> to create a global consortium with Dr. Reddy\u2019s Laboratories Ltd. (DRL) and Global Response Aid (GRA) for oral COVID-19 antiviral candidate favipiravir\n<\/li>\n<li>\nWorking with partner DRL to <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FDr.-Reddy%27s-Laboratories%252C-Global-Response-Aid%252C-and-Appili-Therapeutics-Announce-the-Filing-of-an-Application-for-REEQONUS%25E2%2584%25A2-%2528Favipiravir%2529-Tablets-for-the-Treatment-of-COVID-19-Under-Health-Canada%25E2%2580%2599s-Interim-Order&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=support+the+filing+of+an+application+under+Health+Canada%26%238217%3Bs+interim+order&amp;index=2&amp;md5=5d82714e602ab4549dcc631da550737f\">support the filing of an application under Health Canada\u2019s interim order <\/a>for favipiravir oral tablets (REEQONUS in Canada) on behalf of the global consortium\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FFirst-Patient-Dosed-in-Appili-Therapeutics%25E2%2580%2599-Phase-3-Clinical-Trial-of-Avigan%25C2%25AE-Tablets-%28Favipiravir%29-for-the-Treatment-of-COVID-19-in-the-United-States&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=Dosing+the+first+participant&amp;index=3&amp;md5=6f6d7ee71b092c5a71d69f692d2895b9\">Dosing the first participant<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Provides-Enrollment-Update-for-Its-Phase-3-PRESECO-Trial-Evaluating-the-Oral-Antiviral-Favipiravir-as-an-Early-Treatment-in-COVID-19-&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=activating+over+50%25+of+the+planned+sites+in+the&amp;index=4&amp;md5=c06a36e886be5f799a0dc83bc15227c4\">activating over 50% of the planned sites in the<\/a> U.S. for its Phase 3 PRESECO study evaluating favipiravir for the early treatment of mild-to-moderate COVID-19 infections.\n<\/li>\n<li><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FHealth-Canada-Clears-Appili-Therapeutics-for-New-Phase-3-Clinical-Trial-to-Evaluate-Avigan-Tablets-%2528Favipiravir%2529-in-the-Prevention-of-COVID-19-in-Exposed-Individuals-in-the-Community-&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=Receiving+a+%27No+Objection+Letter+%28NOL%29%27+from+Health+Canada&amp;index=5&amp;md5=f68a5a3322187d4f58e92197528e402d\">Receiving a &#8216;No Objection Letter (NOL)&#8217; from Health Canada<\/a> to initiate the Phase 3 PEPCO study evaluating favipiravir for the prevention of COVID-19 in exposed individuals in the community setting.\n<\/li>\n<li>\nAppointing <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Appoints-Drug-Development-Executive-Don-Cilla-to-the-Newly-Created-Position-of-Chief-Development-Officer&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=Don+Cilla&amp;index=6&amp;md5=722faa5ee8c1cd7f53d5b3e9e6242713\">Don Cilla<\/a> to the role of Chief Development Officer and veteran healthcare executive <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fnewsfeed%2FAppili-Therapeutics-Appoints-Veteran-Healthcare-Executive-Rochelle-Stenzler-to-its-Board-of-Directors&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=Rochelle+Stenzler&amp;index=7&amp;md5=e95d245a31239ff372714d74f8972e02\">Rochelle Stenzler<\/a> to its Board of Directors.\n<\/li>\n<\/ul>\n<p>\n\u201cWith COVID-19 infections soaring across the globe, we believe that a multifaceted approach, including vaccines, oral antivirals, and effective public health strategies are necessary to reduce the spread and the impact of these serious infections,\u201d said<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.appilitherapeutics.com%2Fleadership&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=Dr.+Armand+Balboni%2C+Chief+Executive+Officer+of+Appili+Therapeutics&amp;index=8&amp;md5=1caf0e73d6c3eecc106a15d5934b52a0\"> Dr. Armand Balboni, Chief Executive Officer of Appili Therapeutics<\/a>. \u201cWe are committed to being part of this solution. Our team has made considerable progress, working with Health Canada, the US FDA, and our clinical and consortium partners to accelerate our favipiravir program. We look forward to continued progress, including an expected interim data readout from our PRESECO study in the coming months, in our mission to address this pandemic.\u201d\n<\/p>\n<p><b>Financial Results<\/b><\/p>\n<p>\nThe Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook \u2013Accounting. All dollar figures are $CAN unless otherwise noted.\n<\/p>\n<p>\nThe net loss and comprehensive loss of $9.34 million or $0.16 loss per share for the nine months ended December 30, 2020 was $5.21 million higher than the net loss and comprehensive loss of $4.13 million or $0.13 loss per share during the nine months ended December 30, 2019. This relates mainly to an increase in research and development expenses by $4.38 million, an increase in general and administration expenses by $1.15 million, an increase in accreted interest of $0.05 million. These increases were offset by a decrease of $0.41 million in business development expenses and an increase of government assistance of $0.09 million.\n<\/p>\n<p>\nAs of December 31, 2020, the Company had cash and short-term investments of $20.29 million, compared to $10.54 million at March 31, 2020. As of February 12, 2021, the Company had 62,578,194 issued and outstanding Common Shares, 4,538,538 stock options and 14,879,919 warrants outstanding.\n<\/p>\n<p>\nThis press release should be read in conjunction with the Company\u2019s unaudited interim condensed financial statements for December 31, 2020 and the related management discussion and analysis (MD&amp;A), copies of which are available on SEDAR at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=9&amp;md5=e5e32384144d38d9587b0cd6ea151e48\">www.sedar.com<\/a>.\n<\/p>\n<p><b>About Appili Therapeutics<\/b><\/p>\n<p>\nAppili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili\u2019s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan\u00ae \/ REEQONUS<sup>TM<\/sup> (favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.AppiliTherapeutics.com&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=www.AppiliTherapeutics.com&amp;index=10&amp;md5=4ad04c846364a82c4327b764753d24c0\">www.AppiliTherapeutics.com<\/a>.\n<\/p>\n<p><i>This news release contains \u201cforward-looking statements\u201d, including with respect to the expected interim data readout timetable for the PRESECO study, which reflect the current expectations of the Company\u2019s management future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as \u201cmay,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cpotential for,\u201d and similar expressions have been used to identify these forward-looking statements. Forward-looking statements involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 24, 2020 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=52378710&amp;newsitemid=20210212005534&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=11&amp;md5=bab6bd17cdb1e495550c0cb5d1dd1a1a\">www.sedar.com<\/a>). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.<\/i><\/p>\n<p><i>The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 coronavirus) at this time.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210212005534\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210212005534\/en\/<\/a><\/span><\/p>\n<p><b><i>Media<\/i><\/b>:<br \/>\n<br \/>Andrea Cohen<br \/>\n<br \/>Sam Brown Inc.<br \/>\n<br \/>T: 917-209-7163<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:andreacohen@sambrown.com\">andreacohen@sambrown.com<\/a><\/p>\n<p><b><i>Investor Relations<\/i><\/b>:<br \/>\n<br \/>Kimberly Stephens, CFO<br \/>\n<br \/>Appili Therapeutics<br \/>\n<br \/>TSX: APLI<br \/>\n<br \/>E: <a rel=\"nofollow\" href=\"mailto:Info@AppiliTherapeutics.com\">Info@AppiliTherapeutics.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 HALIFAX, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the third quarter of its fiscal year 2021, which ended December 31, 2020. Third quarter and recent operational highlights include: Signing a collaboration, development, and supply agreement to create a global consortium with Dr. Reddy\u2019s Laboratories Ltd. (DRL) and Global Response Aid (GRA) for oral COVID-19 antiviral candidate favipiravir Working with partner DRL to support the filing of an application under Health Canada\u2019s interim order for favipiravir oral tablets (REEQONUS in Canada) on behalf of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-435351","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 HALIFAX, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the third quarter of its fiscal year 2021, which ended December 31, 2020. Third quarter and recent operational highlights include: Signing a collaboration, development, and supply agreement to create a global consortium with Dr. Reddy\u2019s Laboratories Ltd. (DRL) and Global Response Aid (GRA) for oral COVID-19 antiviral candidate favipiravir Working with partner DRL to support the filing of an application under Health Canada\u2019s interim order for favipiravir oral tablets (REEQONUS in Canada) on behalf of the &hellip; Continue reading &quot;Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-12T22:08:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021\",\"datePublished\":\"2021-02-12T22:08:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/\"},\"wordCount\":936,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/\",\"name\":\"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-02-12T22:08:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/","og_locale":"en_US","og_type":"article","og_title":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 - Market Newsdesk","og_description":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 HALIFAX, Nova Scotia&#8211;(BUSINESS WIRE)&#8211; Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the third quarter of its fiscal year 2021, which ended December 31, 2020. Third quarter and recent operational highlights include: Signing a collaboration, development, and supply agreement to create a global consortium with Dr. Reddy\u2019s Laboratories Ltd. (DRL) and Global Response Aid (GRA) for oral COVID-19 antiviral candidate favipiravir Working with partner DRL to support the filing of an application under Health Canada\u2019s interim order for favipiravir oral tablets (REEQONUS in Canada) on behalf of the &hellip; Continue reading \"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-12T22:08:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021","datePublished":"2021-02-12T22:08:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/"},"wordCount":936,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/","name":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-02-12T22:08:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210212005534r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/appili-therapeutics-reports-financial-and-operational-results-for-third-quarter-of-fiscal-year-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=435351"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435351\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=435351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=435351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=435351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}